Document Detail


Nitrative inactivation of thioredoxin-1 and its role in postischemic myocardial apoptosis.
MedLine Citation:
PMID:  16966583     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: Intracellular proteins involved in oxidative stress and apoptosis are nitrated in diseased tissues but not in normal tissues; definitive evidence to support a causative link between a specific protein that is nitratively modified with tissue injury in a specific disease is limited, however. The aims of the present study were to determine whether thioredoxin (Trx), a novel antioxidant and antiapoptotic molecule, is susceptible to nitrative inactivation and to establish a causative link between Trx nitration and postischemic myocardial apoptosis. METHODS AND RESULTS: In vitro exposure of human Trx-1 to 3-morpholinosydnonimine resulted in significant Trx-1 nitration and almost abolished Trx-1 activity. 3-morpholinosydnonimine-induced nitrative Trx-1 inactivation was completely blocked by MnTE-2-PyP(5+) (a superoxide dismutase mimetic) and markedly attenuated by PTIO (a nitric oxide scavenger). Administration of either reduced or oxidized Trx-1 in vivo attenuated myocardial ischemia/reperfusion injury (>50% reduction in apoptosis and infarct size, P<0.01). However, administration of nitrated Trx-1 failed to exert a cardioprotective effect. In cardiac tissues obtained from ischemic/reperfused heart, significant Trx-1 nitration was detected, Trx activity was markedly inhibited, Trx-1/ASK1 (apoptosis signal-regulating kinase-1) complex formation was abolished, and apoptosis signal-regulating kinase-1 activity was increased. Treatment with either FP15 (a peroxynitrite decomposition catalyst) or MnTE-2-PyP(5+) 10 minutes before reperfusion blocked nitrative Trx inactivation, attenuated apoptosis signal-regulating kinase-1 activation, and reduced postischemic myocardial apoptosis. CONCLUSIONS: These results strongly suggest that nitrative inactivation of Trx plays a proapoptotic role under those pathological conditions in which production of reactive nitrogen species is increased and that antinitrating treatment may have therapeutic value in those diseases, such as myocardial ischemia/reperfusion, in which pathological apoptosis is increased.
Authors:
Ling Tao; Xiangying Jiao; Erhe Gao; Wayne B Lau; Yuexing Yuan; Bernard Lopez; Theodore Christopher; Satish P RamachandraRao; William Williams; Garry Southan; Kumar Sharma; Walter Koch; Xin L Ma
Related Documents :
20724803 - Caulophine protects cardiomyocytes from oxidative and ischemic injury.
12517293 - Effects of leukocyte-depleted reoxygenation on endothelial and ventricular function: wi...
16548963 - Monitor-induced tachycardia in a patient with a rate-responsive pacemaker.
Publication Detail:
Type:  Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't     Date:  2006-09-11
Journal Detail:
Title:  Circulation     Volume:  114     ISSN:  1524-4539     ISO Abbreviation:  Circulation     Publication Date:  2006 Sep 
Date Detail:
Created Date:  2006-09-26     Completed Date:  2006-10-26     Revised Date:  2009-11-19    
Medline Journal Info:
Nlm Unique ID:  0147763     Medline TA:  Circulation     Country:  United States    
Other Details:
Languages:  eng     Pagination:  1395-402     Citation Subset:  AIM; IM    
Affiliation:
Department of Emergency Medicine, Thomas Jefferson University, Philadelphia, PA, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Amino Acid Substitution
Animals
Apoptosis / physiology*
Cardiotonic Agents / antagonists & inhibitors,  pharmacology,  therapeutic use
Cyclic N-Oxides / pharmacology
Free Radical Scavengers / pharmacology
Humans
Imidazoles / pharmacology
MAP Kinase Kinase Kinase 5 / metabolism
MAP Kinase Signaling System / drug effects
Male
Metalloporphyrins / pharmacology,  therapeutic use
Mice
Molsidomine / analogs & derivatives*,  antagonists & inhibitors,  pharmacology
Mutagenesis, Site-Directed
Myocardial Ischemia / metabolism*,  pathology
Myocardial Reperfusion Injury / drug therapy
Myocardium / pathology*
NADP / metabolism
Oxidation-Reduction
Oxidative Stress
Peroxynitrous Acid / pharmacology
Thioredoxins / antagonists & inhibitors*,  therapeutic use
p38 Mitogen-Activated Protein Kinases / metabolism
Grant Support
ID/Acronym/Agency:
2R01HL-63828/HL/NHLBI NIH HHS
Chemical
Reg. No./Substance:
0/Cardiotonic Agents; 0/Cyclic N-Oxides; 0/FeCl tetrakis-2-(triethyleneglycolmonomethylether)pyridylporphyrin; 0/Free Radical Scavengers; 0/Imidazoles; 0/Metalloporphyrins; 0/TXN protein, human; 0/manganese (III) meso-tetrakis(N-ethylpyridinium-2-yl)porphyrin; 14691-52-2/Peroxynitrous Acid; 18390-00-6/2-phenyl-4,4,5,5-tetramethylimidazoline-1-oxyl-3-oxide; 25717-80-0/Molsidomine; 33876-97-0/3-morpholino-sydnonimine; 52500-60-4/Thioredoxins; 53-59-8/NADP; EC 2.7.11.24/p38 Mitogen-Activated Protein Kinases; EC 2.7.11.25/MAP Kinase Kinase Kinase 5

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Functional expression of the TRPM4 cationic current in ventricular cardiomyocytes from spontaneously...
Next Document:  Analytical identification of ideal pulmonary-systemic flow balance in patients with bidirectional ca...